Minerva Neurosciences Stock Performance
| NERV Stock | USD 4.15 0.23 5.87% |
Minerva Neurosciences holds a performance score of 6 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of 3.78, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Minerva Neurosciences will likely underperform. Use Minerva Neurosciences value at risk, as well as the relationship between the kurtosis and price action indicator , to analyze future returns on Minerva Neurosciences.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Minerva Neurosciences are ranked lower than 6 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Minerva Neurosciences showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 5.87 | Five Day Return 1.47 | Year To Date Return 5.87 | Ten Year Return (91.21) | All Time Return (91.43) |
Last Split Factor 1:8 | Last Split Date 2022-06-21 |
1 | Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates | 11/05/2025 |
2 | Minerva Neurosciences Shares Pass Above 50 Day Moving Average Whats Next | 11/18/2025 |
3 | Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Companys Board of Directors | 11/19/2025 |
4 | ProMIS Neurosciences announces 1-for-20 reverse stock split PMN | 11/24/2025 |
5 | ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference | 12/01/2025 |
6 | How Minerva Neurosciences Inc. stock reacts to oil prices - 2025 Top Decliners Technical Pattern Recognition Alerts - Newser | 12/04/2025 |
7 | ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA... | 12/10/2025 |
8 | ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimers Disease | 12/18/2025 |
9 | Acquisition by Remy Luthringer of 2250000 shares of Minerva Neurosciences at 3.98 subject to Rule 16b-3 | 12/22/2025 |
10 | Minerva Neurosciences Upgraded to Hold at Wall Street Zen - MarketBeat | 01/02/2026 |
Minerva Neurosciences Relative Risk vs. Return Landscape
If you would invest 283.00 in Minerva Neurosciences on October 8, 2025 and sell it today you would earn a total of 132.00 from holding Minerva Neurosciences or generate 46.64% return on investment over 90 days. Minerva Neurosciences is currently generating 1.6615% in daily expected returns and assumes 18.9948% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Minerva, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Minerva Neurosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Minerva Neurosciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Minerva Neurosciences, and traders can use it to determine the average amount a Minerva Neurosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0875
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | NERV | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Minerva Neurosciences is performing at about 6% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Minerva Neurosciences by adding it to a well-diversified portfolio.
Minerva Neurosciences Fundamentals Growth
Minerva Stock prices reflect investors' perceptions of the future prospects and financial health of Minerva Neurosciences, and Minerva Neurosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Minerva Stock performance.
| Return On Equity | -6.75 | ||||
| Return On Asset | -0.26 | ||||
| Current Valuation | 157.35 M | ||||
| Shares Outstanding | 6.99 M | ||||
| Price To Earning | 69.58 X | ||||
| Price To Book | 2.68 X | ||||
| Price To Sales | 1.87 X | ||||
| Gross Profit | (5.57 M) | ||||
| EBITDA | 6.02 M | ||||
| Net Income | 1.44 M | ||||
| Cash And Equivalents | 40.22 M | ||||
| Cash Per Share | 7.53 X | ||||
| Total Debt | 60 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 20.41 X | ||||
| Book Value Per Share | (4.95) X | ||||
| Cash Flow From Operations | (19.55 M) | ||||
| Earnings Per Share | (1.85) X | ||||
| Market Capitalization | 26.92 M | ||||
| Total Asset | 37.14 M | ||||
| Retained Earnings | (395.38 M) | ||||
| Working Capital | 19.43 M | ||||
| Current Asset | 33.48 M | ||||
| Current Liabilities | 5.32 M | ||||
About Minerva Neurosciences Performance
Evaluating Minerva Neurosciences' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Minerva Neurosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Minerva Neurosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -116.4 K | -122.2 K | |
| Return On Tangible Assets | 0.06 | 0.06 | |
| Return On Capital Employed | (0.57) | (0.60) | |
| Return On Assets | 0.03 | 0.04 |
Things to note about Minerva Neurosciences performance evaluation
Checking the ongoing alerts about Minerva Neurosciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Minerva Neurosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Minerva Neurosciences is way too risky over 90 days horizon | |
| Minerva Neurosciences appears to be risky and price may revert if volatility continues | |
| Minerva Neurosciences has high likelihood to experience some financial distress in the next 2 years | |
| Minerva Neurosciences currently holds about 40.22 M in cash with (19.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.53, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 22.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from news.google.com: Minerva Neurosciences Upgraded to Hold at Wall Street Zen - MarketBeat |
- Analyzing Minerva Neurosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Minerva Neurosciences' stock is overvalued or undervalued compared to its peers.
- Examining Minerva Neurosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Minerva Neurosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Minerva Neurosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Minerva Neurosciences' stock. These opinions can provide insight into Minerva Neurosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Minerva Stock Analysis
When running Minerva Neurosciences' price analysis, check to measure Minerva Neurosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Minerva Neurosciences is operating at the current time. Most of Minerva Neurosciences' value examination focuses on studying past and present price action to predict the probability of Minerva Neurosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Minerva Neurosciences' price. Additionally, you may evaluate how the addition of Minerva Neurosciences to your portfolios can decrease your overall portfolio volatility.